



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/573,868	03/29/2006	Tomoko Asakawa	074129-0541	7047
22428	7590	10/31/2007	EXAMINER	
FOLEY AND LARDNER LLP			SUTTON, DARRYL C	
SUITE 500			ART UNIT	PAPER NUMBER
3000 K STREET NW			4133	
WASHINGTON, DC 20007				
MAIL DATE		DELIVERY MODE		
10/31/2007		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/573,868	ASAKAWA, TOMOKO	
	Examiner	Art Unit	
	Darryl C. Sutton	4133	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 29 March 2006.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-8 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-8 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date See Continuation Sheet.
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) Notice of Informal Patent Application
- 6) Other: _____.

Continuation of Attachment(s) 3). Information Disclosure Statement(s) (PTO/SB/08), Paper No(s)/Mail Date :3/29/2006, 11/20/2006, 4/30/2007 .

DETAILED ACTION

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 4 and 7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The word "use" in the claims renders the claims indefinite. Applicant has not clearly pointed out or claimed the subject matter of claims 4 and 7.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 4 and 7 provide for the use of a dipeptidyl peptidase IV inhibitor, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claims 4 and 7 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under

35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd. v. Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-8 are rejected under 35 U.S.C. 102(b) as being anticipated by Ahren et al. (Diabetes Care, 2002).

The claims are drawn to compounds to treat diabetes with sulfonylurea secondary failure comprised of dipeptidyl peptidase IV (DDP-IV), and methods of diabetes treatment with the compounds.

Ahren et al. teaches a compound, NVP DPP-IV, an inhibitor of DPP-IV, used to effectively treat type II diabetes in humans (page 869, Objective, page 872, Conclusion, 1st paragraph). Ahren et al. also teaches that GLP-1 is a hormone that acts as an incretin (causes release of insulin from beta cells), and that GLP-1 is rapidly degraded by DPP-IV (page 869, 1st paragraph). If the compound was used to treat type 2 diabetes, it would inherently treat diabetes with sulfonylurea failure from sulfonylurea compounds and from fast acting insulin secretagogues since it would still inhibit DPP-IV and prevent the degradation of GLP-1 hormones. Preventing the degradation of

GLP-1 hormones would allow them to function to increase the release of insulin from beta cells.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-8 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ahren et al. (Eur. J. Pharmacol., 2000) in view of Nauck et al. (Diabetes Care, 1998).

The claims are drawn to compounds to treat diabetes with sulfonylurea secondary failure comprised of dipeptidyl peptidase IV (DPP-IV), and methods of diabetes treatment with the compounds.

Ahren et al. teaches the use of a compound, valine-pyrrolidide, an inhibitor of DPP-IV administered to increase plasma GLP-1 levels (page 239, Abstract); and that it was accompanied by markedly increased insulin secretion and improved glucose tolerance (page 244, 3rd paragraph).

Ahren et al. does not teach that the inhibitor of DPP-IV can be used to treat diabetes with sulfonylurea secondary failure.

Nauck et al. teaches that GLP-1 stimulated insulin secretion in mild diabetic patients and in patients who were in poor metabolic control on sulfonylurea treatment,

i.e. at the point of sulfonylurea secondary failure (page 1925, 3rd column, 1st paragraph, page 1928, Conclusions).

At the time of the invention it would have been obvious to use the methods and the inhibitor of DPP-IV of Ahren et al. to treat diabetes with sulfonylurea secondary failure since the compound increased levels of GLP-1, and would therefore stimulate insulin secretion in patients with diabetes with sulfonylurea secondary function.

All claims are rejected.

Conclusion

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Darryl C. Sutton whose telephone number is (571)270-3286. The examiner can normally be reached on M-Th from 7:30AM to 5:00PM and on Fr from 7:30AM-4:00PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Stucker, can be reached on M-Th from 8:00AM-4:00PM. The fax

Art Unit: 4133

phone number for the organization where this application or proceeding is assigned is

571-273-8300.

DCS


JEFFREY STUCKER
SUPERVISORY PATENT EXAMINER